Atika Capital Management’s AbbVie ABBV Stock Holding History

Atika Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-30,000	Closed	-$1.95M	–	77
2017 Q1	$1.95M	Buy	+30,000	New	+$1.89M	0.96%	47

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Atika Capital Management's ABBV Position: Q2 2018 in Review

Atika Capital Management sold out of AbbVie (ABBV) in Q2 2018, closing a stake of 25,000 shares — an estimated $2.37M sold.

Atika Capital Management first reported a position in ABBV in Q2 2014 and held it in 5 quarters. The position peaked at $4.16M in Q3 2014. 1,996 funds tracked by Wall St. Rank hold ABBV as of Q2 2018.

Atika Capital Management reported no remaining AbbVie position as of Q2 2018 after selling out during the quarter.
Atika Capital Management sold 25,000 AbbVie shares in Q2 2018, an estimated $2.37M.
Atika Capital Management first reported a position in AbbVie in Q2 2014 and held it in 5 quarters.
Atika Capital Management's AbbVie position peaked at $4.16M in Q3 2014.
1,996 funds tracked by Wall St. Rank held AbbVie as of Q2 2018.

Based on Atika Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.